Genomic and bioinformatic analyses of cells prepared from basal/squamous cell carcinoma, carcinoma of breast and melanoma demonstrated that simultaneous targeting of IL-6, VEGF-A and MFGE-8 (lactadherin), optionally with inhibition of IL-8, seems to be beneficial in cancer therapy [69]. Here, MFGE8 is linked to breast carcinoma.